1 2 3 4 5 6 UNITED STATES DISTRICT COURT FOR THE 7 WESTERN DISTRICT OF WASHINGTON AT SEATTLE 8 ) 9 |] ALICIA ROSE and LARRY DUNNING, | ) CASE NO. 2:20-cv-00716-BJR ) 10 Plaintiffs, —) ORDER GRANTING IN PART AND ) DENYING IN PART PLAINTIFFS’ v. ) MOTION TO EXCLUDE CERTAIN ) OPINIONS AND TESTIMONY AND 12 || BOSTON SCIENTIFIC CORPORATION, ) DENYING DEFENDANT’S MOTION TO ) EXCLUDE CERTAIN OPINIONS AND 13 Defendant. ) TESTIMONY
14 15 1. INTRODUCTION 16 Before the Court are two motions to exclude expert opinions and testimony. Plaintiffs 17 18 move to exclude certain opinions of Dr. Steven Swift. Dkt. Nos. 42, 43. Defendants move to
19 exclude certain opinions of Dr. Neeraj Kohli. Dkt. No. 44. Having reviewed the motions, the 20 || oppositions thereto, the record of the case, and the relevant legal authorities, the Court will grant 21 part and deny in part Plaintiffs’ motion and deny Defendant’s motion. The reasoning for the 22 |! Court’s decision follows. 23 Il. BACKGROUND 24 The Court laid out the background of this case in its recent Order Granting in Part and 25
Denying in Part Defendant’s Motion for Summary Judgment. See Dkt. No. 71. In brief, the case
7 involves the transobturator midurethral sling, known as the Obtryx Device, which Ms. Rose had 3 || surgical implanted to treat her stress urinary incontinence, but now complains is defective. Both 4 || parties now move to exclude certain opinions and testimony of the other’s case-specific expert. 5 I. LEGAL STANDARD 6 Federal Rule of Evidence 702 provides that an expert qualified by “knowledge, skill, 7 experience, training, or education may testify in the form of an opinion or otherwise” if that 8 testimony meets certain indicia of relevance and reliability. FED. R. Evi. 702;' see also United 9 10 States v. Ruvalcaba-Garcia, 923 F.3d 1183, 1188 (9th Cir. 2019) (quoting Daubert v. Merrell Dow 11 || Pharm., Inc., 509 U.S. 579, 597 (1993)) (“[b]efore admitting expert testimony into evidence, the 12 || district court must perform a ‘gatekeeping role’ of ensuring that the testimony is both ‘relevant’ 13 | and ‘reliable’ under Rule 702”). Testimony is relevant where “the evidence logically advance[s] M4 a material aspect of the party’s case,” Estate of Barabin v. AstenJohnson, Inc., 740 F.3d 457, 463 15 (9th Cir. 2014) (quoting Cooper v. Brown, 510 F.3d 870, 942 (9th Cir. 2007)), and reliable where 16 it has “a reliable basis in the knowledge and experience of the relevant discipline,” id. (quoting 18 Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 149 (1999)). 19 20 || ————_ 21 full, Rule 702 provides A witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify 23 in the form of an opinion or otherwise if: (a) the expert's scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the 24 testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliably applied the principles and methods to the facts of the case. 25 FED. R. Evip. 702.
The reliability inquiry is a “flexible one’” and while the Supreme Court has suggested several factors helpful in determining reliability, see Daubert, 509 U.S. at 592-94, District Courts 2 Pp g y. 3 || are given “broad latitude in determining the appropriate form of the inquiry,” United States v. 4 || Wells, 879 F.3d 900, 934 (9th Cir. 2018) (quoting Kumho Tire, 526 U.S. at 150); see also Barabin, 5 |1740 F.3d at 463. The inquiry also favors admission of testimony as “[s]haky but admissible 6 evidence is to be attacked by cross examination, contrary evidence, and attention to the burden of 7 proof, not exclusion.” Primiano v. Cook, 598 F.3d 558, 564 (9th Cir. 2010) (citing Daubert, 509 8 9 U.S. at 596). The party proffering the expert testimony has the burden of establishing its
10 admissibility under a preponderance of the evidence standard. Daubert, 509 U.S. at 592 n.10. 11 IV. PLAINTIFFS’ MOTION TO EXCLUDE TESTIMONY OF STEVEN SWIFT, M.D. 12 3 Plaintiffs’ motion seeks to exclude opinions and testimony by Defendant’s case-specific 14 expert, Dr. Steven Swift,” on three specific topics: (1) the adequacy of the Obtryx Device’s 15 || Directions for Use (“DFU”); (2) complication rates of patients in his own practice; and (3) the 16 || physical properties of the polypropylene mesh used in the Obtryx Device. Dkt. No. 42 at 1. 17 A. Dr. Swift’s Testimony on the Adequacy of the Obtryx Device’s Directions for Use 18 Plaintiffs seek to exclude the opinions and testimony of Dr. Swift as to the adequacy of the 19 Obtryx Device’s DFU, or the warnings therein, claiming that he has conceded to not being 20 qualified to offer such expertise. Dkt. No. 42 at 1; Dkt. No. 43 at 4-6. As evidence of this claimed 21
23 2 Dr. Swift is a board-certified urogynecologist and is currently the Director of the Division of Urogynecology, Vice 24 Chair of the Institutional Review Board for investigator-initiated studies, and a tenured Professor in the Department of Obstetrics and Gynecology at the Medical University of South Carolina. See Dkt. No. 42-3 (Curriculum Vitae of 25 Steven Swift, M.D.).
concession to lack of expertise, Plaintiffs point to statements Dr. Swift made during his deposition, 7 including: “I don’t understand what a DFU is for because prior to this litigation, ’'ve never even 3 || heard the term,” Dkt. No. 42-2 at 63:7-9, and “I’m familiar with FDA requirements. I am by no 4 ||means an expert in FDA regulatory...,” id. at 63:17-64:23. Plaintiffs also point to six relevant 5 || statements in Dr. Swift’s expert report (Dkt. No. 42-1). Dkt. No. 43 at 4. 6 Defendant contends that the opinions and testimony that Dr. Swift will proffer on this subject are well within his expertise. Dkt. No. 46 at 3-6. Defendant points out that Dr. Swift will not be testifying on the adequacy of the DFU in general, but, rather, he will “identify specific mesh
10 complications alleged by Plaintiffs or their experts and opine that such complications are included 11 the Obtryx DFU.” Jd. at 4. 12 The Court has reviewed both Dr. Swift’s expert report and his deposition. Dr. Swift is a 13 highly qualified and experienced doctor in this field which, according to the MDL that preceded 4 this Court, makes him fit to “opine about the risks of the [Obtryx Device] and pelvic mesh surgery and whether those risks were adequately expressed [i]n the [Obtryx Device’s DFU].” Huskey v.
7 Ethicon, Inc., 29 F. Supp. 3d 691, 704 (S.D. W. Va. 2014). As that Court held, Dr.
Free access — add to your briefcase to read the full text and ask questions with AI
1 2 3 4 5 6 UNITED STATES DISTRICT COURT FOR THE 7 WESTERN DISTRICT OF WASHINGTON AT SEATTLE 8 ) 9 |] ALICIA ROSE and LARRY DUNNING, | ) CASE NO. 2:20-cv-00716-BJR ) 10 Plaintiffs, —) ORDER GRANTING IN PART AND ) DENYING IN PART PLAINTIFFS’ v. ) MOTION TO EXCLUDE CERTAIN ) OPINIONS AND TESTIMONY AND 12 || BOSTON SCIENTIFIC CORPORATION, ) DENYING DEFENDANT’S MOTION TO ) EXCLUDE CERTAIN OPINIONS AND 13 Defendant. ) TESTIMONY
14 15 1. INTRODUCTION 16 Before the Court are two motions to exclude expert opinions and testimony. Plaintiffs 17 18 move to exclude certain opinions of Dr. Steven Swift. Dkt. Nos. 42, 43. Defendants move to
19 exclude certain opinions of Dr. Neeraj Kohli. Dkt. No. 44. Having reviewed the motions, the 20 || oppositions thereto, the record of the case, and the relevant legal authorities, the Court will grant 21 part and deny in part Plaintiffs’ motion and deny Defendant’s motion. The reasoning for the 22 |! Court’s decision follows. 23 Il. BACKGROUND 24 The Court laid out the background of this case in its recent Order Granting in Part and 25
Denying in Part Defendant’s Motion for Summary Judgment. See Dkt. No. 71. In brief, the case
7 involves the transobturator midurethral sling, known as the Obtryx Device, which Ms. Rose had 3 || surgical implanted to treat her stress urinary incontinence, but now complains is defective. Both 4 || parties now move to exclude certain opinions and testimony of the other’s case-specific expert. 5 I. LEGAL STANDARD 6 Federal Rule of Evidence 702 provides that an expert qualified by “knowledge, skill, 7 experience, training, or education may testify in the form of an opinion or otherwise” if that 8 testimony meets certain indicia of relevance and reliability. FED. R. Evi. 702;' see also United 9 10 States v. Ruvalcaba-Garcia, 923 F.3d 1183, 1188 (9th Cir. 2019) (quoting Daubert v. Merrell Dow 11 || Pharm., Inc., 509 U.S. 579, 597 (1993)) (“[b]efore admitting expert testimony into evidence, the 12 || district court must perform a ‘gatekeeping role’ of ensuring that the testimony is both ‘relevant’ 13 | and ‘reliable’ under Rule 702”). Testimony is relevant where “the evidence logically advance[s] M4 a material aspect of the party’s case,” Estate of Barabin v. AstenJohnson, Inc., 740 F.3d 457, 463 15 (9th Cir. 2014) (quoting Cooper v. Brown, 510 F.3d 870, 942 (9th Cir. 2007)), and reliable where 16 it has “a reliable basis in the knowledge and experience of the relevant discipline,” id. (quoting 18 Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 149 (1999)). 19 20 || ————_ 21 full, Rule 702 provides A witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify 23 in the form of an opinion or otherwise if: (a) the expert's scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the 24 testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliably applied the principles and methods to the facts of the case. 25 FED. R. Evip. 702.
The reliability inquiry is a “flexible one’” and while the Supreme Court has suggested several factors helpful in determining reliability, see Daubert, 509 U.S. at 592-94, District Courts 2 Pp g y. 3 || are given “broad latitude in determining the appropriate form of the inquiry,” United States v. 4 || Wells, 879 F.3d 900, 934 (9th Cir. 2018) (quoting Kumho Tire, 526 U.S. at 150); see also Barabin, 5 |1740 F.3d at 463. The inquiry also favors admission of testimony as “[s]haky but admissible 6 evidence is to be attacked by cross examination, contrary evidence, and attention to the burden of 7 proof, not exclusion.” Primiano v. Cook, 598 F.3d 558, 564 (9th Cir. 2010) (citing Daubert, 509 8 9 U.S. at 596). The party proffering the expert testimony has the burden of establishing its
10 admissibility under a preponderance of the evidence standard. Daubert, 509 U.S. at 592 n.10. 11 IV. PLAINTIFFS’ MOTION TO EXCLUDE TESTIMONY OF STEVEN SWIFT, M.D. 12 3 Plaintiffs’ motion seeks to exclude opinions and testimony by Defendant’s case-specific 14 expert, Dr. Steven Swift,” on three specific topics: (1) the adequacy of the Obtryx Device’s 15 || Directions for Use (“DFU”); (2) complication rates of patients in his own practice; and (3) the 16 || physical properties of the polypropylene mesh used in the Obtryx Device. Dkt. No. 42 at 1. 17 A. Dr. Swift’s Testimony on the Adequacy of the Obtryx Device’s Directions for Use 18 Plaintiffs seek to exclude the opinions and testimony of Dr. Swift as to the adequacy of the 19 Obtryx Device’s DFU, or the warnings therein, claiming that he has conceded to not being 20 qualified to offer such expertise. Dkt. No. 42 at 1; Dkt. No. 43 at 4-6. As evidence of this claimed 21
23 2 Dr. Swift is a board-certified urogynecologist and is currently the Director of the Division of Urogynecology, Vice 24 Chair of the Institutional Review Board for investigator-initiated studies, and a tenured Professor in the Department of Obstetrics and Gynecology at the Medical University of South Carolina. See Dkt. No. 42-3 (Curriculum Vitae of 25 Steven Swift, M.D.).
concession to lack of expertise, Plaintiffs point to statements Dr. Swift made during his deposition, 7 including: “I don’t understand what a DFU is for because prior to this litigation, ’'ve never even 3 || heard the term,” Dkt. No. 42-2 at 63:7-9, and “I’m familiar with FDA requirements. I am by no 4 ||means an expert in FDA regulatory...,” id. at 63:17-64:23. Plaintiffs also point to six relevant 5 || statements in Dr. Swift’s expert report (Dkt. No. 42-1). Dkt. No. 43 at 4. 6 Defendant contends that the opinions and testimony that Dr. Swift will proffer on this subject are well within his expertise. Dkt. No. 46 at 3-6. Defendant points out that Dr. Swift will not be testifying on the adequacy of the DFU in general, but, rather, he will “identify specific mesh
10 complications alleged by Plaintiffs or their experts and opine that such complications are included 11 the Obtryx DFU.” Jd. at 4. 12 The Court has reviewed both Dr. Swift’s expert report and his deposition. Dr. Swift is a 13 highly qualified and experienced doctor in this field which, according to the MDL that preceded 4 this Court, makes him fit to “opine about the risks of the [Obtryx Device] and pelvic mesh surgery and whether those risks were adequately expressed [i]n the [Obtryx Device’s DFU].” Huskey v.
7 Ethicon, Inc., 29 F. Supp. 3d 691, 704 (S.D. W. Va. 2014). As that Court held, Dr. Swift “need 1g || not be an expert on product warnings per se” but, instead, “is qualified to testify about the risks of 19 ||implanting the [Obtryx Device] and whether those risks were adequately expressed [1i]n the 20 || [Obtryx Device’s DFU]” including “the completeness and accuracy of [Defendant’s] warning 71 and—‘it follows from that—the extent to which any inaccuracies or omissions could either deprive a reader or mislead a reader of what the risks and benefits’ of the Obtryx Device was when the warnings were published.” J/d. at 719 (quoting Jn re Diet Drugs (Phentermine, Fenfluramine, 5 Dexfenfluramine) Prods. Liab. Litig., MDL 1203, 2000 WL 876900, at *11 (E.D. Pa. June 20,
2000)); see also Tyree v. Bos. Sci. Corp., No. 12-cv-08633, 2014 WL 5486694, at *47 (S.D. W.
7 Va. Oct. 29, 2014). 3 Reviewing the statements identified by Plaintiffs in Dr. Swift’s report, and the report as a 4 || whole, the Court concludes that Dr. Swift has not strayed into regulatory interpretation but, instead, 5 |! has expressed an opinion as to what other doctors and surgeons would find relevant in the DFUs. 6 As such, the Court will deny Plaintiffs’ motion on these grounds. B. Dr. Swift’s Testimony on Complication Rates of Patients in His Practice Plaintiffs argue that Dr. Swift should not be permitted to testify on complication rates in
10 his own practice. Dkt. No 42 at 1; Dkt. No. 43 at 6-8. Plaintiffs take issue with several statements 1] Dr. Swift’s report in which he opines that, in his practice, complications with the Obtryx Device 12 || are “uncommon,” “rare,” and “consistent with complications reported in the clinical literature.” 13 |! Dkt. No 43 at 6 (quoting 42-1 at 5, 6, 7, 8-9, 11). Such testimony, according to Plaintiffs, is M4 inappropriate because it lacks a verifiable methodology, as Dr. Swift’s practice does not maintain a database tracking patient outcomes and he 1s, therefore, unable to provide a concrete 16 complication rate. Defendant opposes and argues that Dr. Swift should be permitted to testify on
18 opinions developed based on his own experience. Dkt. No. 46 at 8-10. 19 It is well established that an expert may testify based on his “personal knowledge or 20 || experience.” Kumho Tire, 526 U.S. at 150 (“relevant reliability concerns may focus upon personal 21 22 23 To the extent that Plaintiffs argue that Dr. Swift’s testimony should be excluded because the MDL Court excluded his testimony on the Obtryx Device’s DFU in Flores-Banda v. Bos. Sci. Corp., No. 13-cv-04434, 2016 WL 24 || 2939522, at *17 (S.D. W. Va. May 19, 2016), the Court agrees with Defendant that Dr. Swift has not limited his testimony in this case as he did there. See Flores-Banda, 2016 WL 2939522, at *17 (“[i]n his deposition, Dr. Swift 25 stated that he had no intention of opining on the DFU”).
knowledge or experience”); see also FED. R. EVID. 702 (an expert qualified by “knowledge, skill,
experience, training, or education may testify”); In re: Ethicon, Inc. Pelvic Repair Sys. Prod. Liab. 3 || Litig., No. MDL 2327, 2016 WL 4944331, at *3 (S.D. W. Va. Aug. 31, 2016) (Doctors can “offer 4 || general complications opinions based on [their] clinical observations”). At the same time, expert 5 testimony should be “the product of reliable principles and methods.” FED. R. EVID. 702(c). Thus, 6 as the MDL Court has already established, experts cannot testify on personal complication rates where they have not provided “objective data to back up [such] assertion[s].” Eghnayem v. Bos. Sci. Corp., 57 F. Supp. 3d 658, 701 (S.D. W. Va. 2014). That Court consistently prohibited experts 10 from testifying on specific personal complication rates where the expert was unable to provide 11 || verifiable data from the expert’s practice. See Ethicon, 2016 WL 4944331, at *3; In re: Ethicon, 12 || Inc. Pelvic Repair Sys. Prod. Liab. Litig., No. 2327, 2016 WL 4958312, at *3 (S.D. W. Va. Aug. 13 25, 2016); Eghnayem, 57 F. Supp. 3d at 701; Tyree v. Bos. Sci. Corp., 54 F. Supp. 3d 501, 521, 4 523 (S.D. W. Va. 2014), as amended (Oct. 29, 2014); Huskey, 29 F. Supp. 3d at 721; In re CR. Bard, Inc., 948 F. Supp. 2d 589, 606-07 (S.D. W. Va. 2013), on reconsideration in part (June 14,
7 2013). 18 Based on these principles, the Court will exclude Dr. Swift’s testimony on complications 19 in his personal practice. His testimony that complications are “rare” or “uncommon” are 20 || inadmissible as both unsupported by verifiable data and irrelevant to the questions at hand. There 71 are only two reasons why Defendant would want to introduce such testimony. The first, as Dr. Swift provided in his report, is to relate his complications rates with those occurring in the general population as expressed in medical literature. He may not do so, however, because he has not
5 provided the data from his practice to quantify his actual rates. Thus, the terms “rare” or
“uncommon” are vague and unverifiable.
7 The second reason to introduce such testimony is to provide observations limited only to 3 || his own practice, which aligns with an expert’s ability to testify on personal knowledge and 4 || experience. Again, however, such terms are devoid of relevance without quantifiability. Further, 5 || observations from his own practice are not relevant to the trier of fact as his own practice is not 6 the subject of this litigation. See FED. R. EvID. 702(a) (expert may testify if “the expert’s .. . knowledge will help the trier of fact to understand the evidence or to determine a fact in issue”).
9 Based on the foregoing, the Court will grant Plaintiffs’ motion on these grounds and exclude Dr.
10 Swift's testimony on complication rates in his personal practice. 11 C. Dr. Swift’s Testimony on the Physical Properties of Polypropylene Mesh 12 Plaintiffs urge the Court to exclude testimony by Dr. Swift as to the physical properties of 13 the polypropylene mesh used in the Obtryx Device, including that it does not degrade, contract, or M4 elicit a continual foreign body response. Dkt. No. 42 at 1; Dkt. No. 43 at 8-9. According to Plaintiffs, Dr. Swift lacks expertise in biomaterials, biomedical engineering, and medical device manufacture and design. Defendant counters that Dr. Swift is qualified to opine on the
18 polypropylene as a medical expert who frequently sees the material in his practice as well as 19 || medical literature. Dkt. No. 46 at 6-8. 20 As stated above, Dr. Swift is qualified by experience to discuss the cases he has treated 21 involving degradation, contraction, and continual foreign body response. His report does not offer 22 opinions pertinent to biomedical engineering, but, instead, observations rooted in his experience as a practitioner. See Dkt. No. 42-1 at 11 (“7 have not seen evidence of polypropylene degradation,
95 systemic infection, mesh shrinkage/contracture, or other unexpected adverse outcomes following
placement of an Obtryx sling.”), 14 see no evidence of mesh degradation, contracture or
7 infection caused by the Obtryx sling Ms. Rose received”’) (emphasis added). 3 The Court is also mindful that the MDL Court reserved judgment on this question. See 4 || Flores-Banda, 2016 WL 2939522, at *16-17. That Court determined that it was “without 5 || sufficient information at this time to determine the reliability of Dr. Swift’s opinions on the physical properties of mesh.” /d. at *17. Having reviewed Dr. Swift’s expert report in this case, 7 this Court is convinced that his experience with such materials based on personal observation is 8 9 relevant and would be helpful to the jury. See FED. R. EVID. 702(a). The Court will, therefore, 10 allow Dr. Swift to testify on this subject. 11 Vv. DEFENDANT’S MOTION TO EXCLUDE TESTIMONY OF DR. NEERAJ KOHLI, M.D. 12 3 Defendant moves to exclude the testimony of Plaintiffs’ expert witness, Dr. Neeraj Kohli,’
14 in which he opines on the causation of Ms. Rose’s complications and attributes them to the Obtryx 15 || Device. Dkt. No. 44. Defendant claims Dr. Kohli conceded in his deposition that he does not have 16 ||a reasonable basis to conclude that the Obtryx Device “caused Plaintiff's worsening defecator y 8 y 17 dysfunction and hypertonic pelvic floor.” Jd. at 2.° Plaintiffs explain that Dr. Kohli will not testify 18 19 20 91 Dr. Kohli is a board certified obstetrician-gynecologists specializing in urogynecology and currently serves as Medical Director for Boston Urogyn. He also maintains an academic teaching appointment at Harvard Medical 22 || School and teaches in the Ob/Gyn Residency Program at Brigham and Women’s Hospital in Boston. See Dkt. No. 44-1 at 2-4. 23 ||s Specifically, Defendant cites the following portion of Dr. Kohli’s deposition 24 Q. Just so [have it clear you're not offering an opinion to a reasonable degree of medical certainty as to the cause of Ms. Rose’s defecatory dysfunction, correct? 95 A. Correct. Q. And you're not offering an opinion to a reasonable degree of medical certainty as to the cause of her
as to the cause of these conditions, but, rather, that the Obtryx Device exacerbated them. Dkt. No.
7 47 at 3-5. 3 As Plaintiffs poimt out, in his expert report, Dr. Kohli does not address the root causes of 4 || Ms. Rose’s complications, but, instead, concentrates on his contention that the Obtryx Device had 5 lla worsening effect on her condition. /d. at 4-5. Dr. Kohli deposition testimony is consistent with 6 this. See Dkt. No. 47-2 at 38:11-23. The Court, therefore, will deny Defendant’s motion. ’ VI. CONCLUSION For the foregoing reasons, the Court ORDERS as follows:
10 1. Plaintiffs’ motion to exclude Dr. Swift’s testimony on the adequacy of the Obtryx 11 Device’s Directions for Use is DENIED; 12 2. Plaintiffs’ motion to exclude Dr. Swift’s testimony on complication rates of patients in 13 his practice is GRANTED; 3. Plaintiffs’ motion to exclude Dr. Swift’s Testimony on the physical properties of polypropylene mesh is DENIED; and 4. Defendant’s motion to exclude the testimony of Dr. Kohli is DENIED.
18 DATED this 21st day of July, 2020. 19 Abas [bain 20 BARBARA J.ROTHSTEIN > UNITED STATES DISTRICT JUDGE
22 23 24 hyper tonic pelvic floor, correct? A. Correct. 25 Dkt. No. 44-2 at 58:4-14.